TREOVIR

Treovir was founded in 2019 to develop and commercialize G207 for recurrent glioblastoma in children... Treovir's G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects. Treovir strives to change the course of brain tumor therapies, improve survival rates and quality of life and provide hope.

Also known as: Treovir LLC, Treovir, Inc.